NCT06446778 Pipeline Embolization for Intracranial Aneurysms
| NCT ID | NCT06446778 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhujiang Hospital |
| Condition | Efficacy, Self |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2022-09-01 |
| Primary Completion | 2027-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2022-09-01 with a primary completion date of 2027-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study collected the clinical, laboratory, and imaging data from patients with intracranial aneurysms, who underwent Pipeline implantation. The purpose of this study is to observe the safety, effcacy, and haemodynamics after Pipeline embolization.
Eligibility Criteria
Inclusion criteria: 1. Aged 22 to 75 years old, male or non-pregnant female; 2. UIA was diagnosed by CTA, MRA, or DSA; 3. The size of aneurysms is between 3 to 25mm; 4. Understands the nature of the procedure and provision of written informed consent; 5. Indications for FD implantation with or without adjunctive coiling; 6. Is willing to return to the investigational site for follow-up according to our protocol. Exclusion criteria: 1. With contraindications to flow-diversion treatment or known allergy to cobalt-chromium alloy or contrast medium; 2. Pregnancy or lactation; 3. Coexist with other vascular lesions (coronary artery disease, abdominal aortic aneurysm, severe intracranial artery stenosis, arteriovenous malformation, dural arteriovenous fistula, Moyamoya disease, etc.); 4. Parent vessel with a diameter \<2.0 mm or ≥5.0 mm.; 5. Unwilling to be followed up or likely to have poor treatment compliance; 6. Life expectancy less than 3 years; 7. Inability to receive anti-platelet or anticoagulant medication; 8. Severe neurological deficit that renders the patient unable to live independently (modified Rankin score ≥4); 9. Enrollment in another trial or other situations that the researcher deems unsuitable for inclusion in the study.
Contact & Investigator
Chuanzhi Duan, MD
STUDY DIRECTOR
Zhujiang Hospital
Frequently Asked Questions
Who can join the NCT06446778 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, up to 75 Years, studying Efficacy, Self. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06446778 currently recruiting?
Yes, NCT06446778 is actively recruiting participants. Contact the research team at doctor_duanzj@163.com for enrollment information.
Where is the NCT06446778 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06446778 clinical trial?
NCT06446778 is sponsored by Zhujiang Hospital. The principal investigator is Chuanzhi Duan, MD at Zhujiang Hospital. The trial plans to enroll 1,000 participants.